IPO Databook: Acurx Pharmaceuticals (ACXP US) - Sep 2026

99 Views10 Sep 2026 10:06

SUMMARY

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat Gram-positive bacterial infections.
Acurx Pharmaceuticals, a late-stage biopharmaceutical company, received $9.2 million from sales under a Purchase Agreement and may receive up to $2.8 million additional gross proceeds.
The auditor's report includes an explanatory paragraph on the ability to continue as a going concern, and substantial additional capital is needed.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream